No Data
No Data
Jinhe Biotech: 2024 Semi-Annual Report Summary
Jinhe Biotech: 2024 Semi-Annual Report
Jinhe Biotechnology (002688.SZ) released its semi-annual performance, with a net income of 91.0206 million yuan, a year-on-year increase of 1.86%.
Jinhe Biotechnology (002688.SZ) released its 2024 interim report, and the company achieved revenue of 1...
Jinhe Biotechnology (002688.SZ): Net income in the first half of the year was 91.0206 million yuan, a year-on-year increase of 1.86%.
Jinhe Biotechnology (002688.SZ) announced its semi-annual report for 2024, with operating revenue of 1.066 billion yuan, a year-on-year increase of 3.22%; net income attributable to shareholders of the listed company was 91.0206 million yuan, a year-on-year increase of 1.86%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 84.9487 million yuan, a year-on-year increase of 2.14%; basic earnings per share was 0.1166 yuan.
Jinhe Biotechnology (002688.SZ): Currently, there are no drugs available to treat monkeypox virus.
Jinhe Biotechnology (002688.SZ) stated on the investor platform on August 21 that the company invested in Yunnan Rueitai Biological Products Co., Ltd., a subsidiary of Jinhe Youben. The company has CE-certified testing reagents for monkey-pox virus using nucleic acid POCT fluorescence method. The company currently does not have drugs to treat monkeypox virus.
Jinhe Biotechnology (002688.SZ): granted 11.75 million stock options to 25 incentive recipients.
On August 12th, Gelunhui reported that Jinhe Biotechnology (002688.SZ) held the 16th meeting of the sixth board of directors on August 12th, 2024 to review and approve the "Proposal on Granting Stock Options to the Incentive Objects in the 2024 Stock Option Incentive Plan". The company's board of directors believes that the granting conditions for the stock options stipulated in the "2024 Stock Option Incentive Plan of Jinhe Biotechnology Co., Ltd." have been achieved, and agrees to authorize the granting of 11.75 million stock options to 25 eligible incentive objects on August 12th, 2024 at an exercise price of 2.94 yuan per share.
No Data
No Data